Recent approaches to improve the antitumor efficacy of temozolomide

Current Medicinal Chemistry

Volumn 16, Issue 2, 2009, Pages 245-257

  Tentori, Lucio ^a   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cancer; Chemotherapy; DNA repair; Drug resistance; Poly(ADP ribose) polymerase; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; ALPHA2B INTERFERON; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GEMCITABINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IRINOTECAN; ISOTRETINOIN; LOMEGUATRIB; METHOXYAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METOCLOPRAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VINBLASTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ACUTE LEUKEMIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN LYMPHOMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DIARRHEA; DNA METHYLATION; DNA REPAIR; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DNA INTERACTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNE DEFICIENCY; INTESTINE INJURY; IONIZING RADIATION; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; MENINGEAL METASTASIS; METASTASIS INHIBITION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PROGRESSION FREE SURVIVAL; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; VIRUS REACTIVATION; VOMITING; DRUG EFFECT; METABOLISM;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DNA REPAIR; GLIOBLASTOMA; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASES;

EID: 62349087854     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787002718     Document Type: Review

References (139)

1. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352, 987
2. Sathornsumetee, S.; Rich, J.N.; Reardon, D.A. Diagnosis and treatment of high-grade astrocytoma. Neurol. Clin., 2007, 25, 1111.
3. Balmaceda, C.; Peereboom, D.; Pannullo, S.; Cheung, Y.K.; Fisher, P.G.; Alavi, J.; Sisti, M.; Chen, J.; Fine, R.L. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer, 2008, 112, 1139.
4. Raizer, J.J.; Hwu, W.J.; Panageas, K.S.; Wilton, A.; Baldwin, D.E.; Bailey, E.; von Althann, C.; Lamb, L.A.; Alvarado, G.; Bilsky, M.H.; Gutin, P.H. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol., 2008, 10, 199.
5. www.clinicaltrials.gov
6. Bleehen, N.M.; Newlands, E.S.; Lee, S.M.; Thatcher, N.; Selby, P.; Calvert, A.H.; Rustin, G.J.; Brampton, M.; Stevens, M.F. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 1995, 13, 910.
7. Middleton, M.R.; Grob, J.J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; Dreno, B.; Henz, M.; Schadendorf, D.; Kapp, A.; Weiss, J.; Fraass, U.; Statkevich, P.; Muller, M.; Thatcher, N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol., 2000, 18, 158.
8. Abrey, L.E., Christodoulou, C. Temozolomide for treating brain metastases. Semin. Oncol., 2001, 28(4 Suppl 13), 34.
9. Biasco, G.; Pantaleo, M.A.; Casadei, S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med., 2001, 345, 621.
10. Douglas, J.G.; Margolin, K. The treatment of brain metastases from malignant melanoma. Semin. Oncol., 2002, 29, 518
11. Paul, M.J.; Summers, Y.; Calvert, A.H.; Rustin, G.; Brampton, M.H.; Thatcher, N.; Middleton, M.R. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res., 2002, 12, 175.
12. Kiebert, G.M.; Jonas, D.L.; Middleton, M.R. Health-related quality of life in patients with advanced metastatic melanoma: Results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest., 2003, 21, 821.
13. Agarwala, S.S.; Kirkwood, J.M.; Gore, M.; Dreno, B.; Thatcher, N.; Czarnetski, B.; Atkins, M.; Buzaid, A.; Skarlos, D.; Rankin, EM. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J. Clin. Oncol., 2004, 22, 2101.
14. Seiter, K.; Liu, D.; Loughran, T.; Siddiqui, A.; Baskind, P.; Ahmed, T. Phase I study of temozolomide in relapsed/refractory acute leukemia. J. Clin. Oncol., 2002, 20, 3249.
15. Garcia del Muro, X.; Lopez-Pousa, A.; Martin, J.; Buesa, J.M.; Martinez-Trufero, J.; Casado, A.; Poveda, A.; Cruz, J.; Bover, I.; Maurel, J.; Spanish Group for Research on Sarcomas. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: A study by the Spanish Group for Research on Sarcomas. Cancer, 2005, 104, 1706.
16. Laber, D.A.; Khan, M.I.; Kloecker, G.H.; Schonard, C.; Taft, B.S.; Salvador, C. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer Biol. Ther., 2007, 6, 840.
17. Horton, T.M.; Thompson, P.A.; Berg, S.L.; Adamson, P.C.; Ingle, A.M.; Dolan, M.E.; Delaney, S.M.; Hedge, M.; Weiss, H.L.; Wu, M.F., Blaney, S.M.; Children's Oncology Group Study. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: A Children's Oncology Group Study. J. Clin. Oncol. 2007, 25, 4922.
18. Omuro, A.M.; Taillandier, L.; Chinot, O.; Carnin, C.; Barrie, M.; Hoang-Xuan, K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J. Neurooncol., 2007, 85, 207.
19. Reni, M.; Zaja, F.; Mason, W.; Perry, J.; Mazza, E.; Spina, M.; Bordonaro, R.; Ilariucci, F.; Faedi, M.; Corazzelli, G.; Manno, P.; Franceschi, E.; Pace, A.; Candela, M.; Abbadessa, A.; Stelitano, C.; Latte, G.; Ferreri, A.J. Temozolomide as salvage treatment in primary brain lymphomas. Br. J. Cancer, 2007, 96, 864.
20. Ekeblad. S.; Sundin, A.; Janson, E.T.; Welin, S.; Granberg, D.; Kindmark, H.; Dunder, K.; Kozlovacki, G.; Orlefors, H.; Sigurd, M.; Oberg, K.; Eriksson, B.; Skogseid, B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res., 2007, 13, 2986.
21. Newlands, E.S.; Stevens, M.F.G.; Wedge, S.R.; Wheelhouse, R.T.; Brock, C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev., 1997, 23, 35.
22. Jen, J.F.; Cutler, D.L.; Pai. S.M.; Batra, V.K.; Affrime, M.B.; Zambas, D.N.; Heft, S.; Hajian, G. Population pharmacokinetics of temozolomide in cancer patients. Pharm. Res., 2000, 17, 1284.
23. Darkes, M.J.M.; Plosker, G.L.; Jarvis, B. Temozolomide: A Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers. Drug Evaluation Am. J. Cancer, 2002, 1, 55.
24. Newlands, E.S.; Blackledge, G.R.; Slack, J.A.; Rustin, G.J.; Smith, D.B.; Stuart, N.S.; Quarterman, C.P.; Hoffman, R.; Stevens, M.F.; Brampton, M.H.; Gibson, A.C. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer, 1992, 65, 287.
25. Su, Y.B.; Sohn, S.; Krown, S.E.; Livingston, P.O.; Wolchok, J.D.; Quinn, C.; Williams, L. Foster, T.; Sepkowitz, K.A.; Chapman, P.B. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J. Clin. Oncol., 2004, 22, 610.
26. Grewal, J.; Dellinger, C.A.; Yung, W.K. Fatal reactivation of hepatitis B with temozolomide. N. Engl. J. Med., 2007, 356, 1591.
27. Su, Y.W.; Chang, M.C.; Chiang, M.F.; Hsieh, R.K. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol., 2005, 71, 315.
28. Brem, S.; Tyler, B.; Li, K.; Pradilla, G.; Legnani, F.; Caplan, J.; Brem, H. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother. Pharmacol., 2007, 60, 643.
29. Kaina, B.; Christmann, M.; Naumann, S.; Roos, WP. MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst), 2007, 6, 1079.
30. Stevens, M.F.; Hickman, J.A.; Langdon, S.P.; Chubb, D.; Vickers, L.; Stone, R.; Baig, G.; Goddard, C.; Gibson, N.W.; Slack, J.A.; Newton, C.; Lunt, E.; Fizames, C.; Lavelle, F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res., 1987, 47, 5846.
31. Mojas, N.; Lopes, M.; Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev., 2007, 21, 3342
32. Tentori, L.; Graziani, G.; Gilberti, S.; Lacal, P.M.; Bonmassar, E.; D'Atri, S. Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia, 1995, 9, 1888.
33. D'Atri, S.; Tentori, L.; Lacal, P.M.; Graziani, G.; Pagani, E.; Benincasa, E.; Zambruno, G.; Bonmassar, E.; Jiricny, J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol., 1998, 54, 334.
34. Hirose, Y.; Berger, M.S.; Pieper, R.O. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res., 2001, 61, 5843.
35. Tentori, L.; Portarena, I.; Torino, F.; Scerrati, M.; Navarra, P.; Graziani, G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia, 2002, 40, 44.
36. Günther, W.; Pawlak, E.; Damasceno, R.; Arnold, H.; Terzis, A.J. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br. J. Cancer, 2003, 88, 463.
37. Fishel, R. Signaling mismatch repair in cancer. Nat. Med., 1999, 5, 1239.
38. Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol., 2006, 7, 335.
39. Mirzoeva, O.K.; Kawaguchi, T.; Pieper, R.O. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol. Cancer Ther., 2006, 5, 2757.
40. Hirose, Y.; Katayama, M.; Berger, M.S.; Pieper, R.O. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J. Neurosurg., 2004, 100, 1060.
41. Hirose, Y.; Katayama, M.; Stokoe, D.; Haas-Kogan, D.A.; Berger, M.S.; Pieper, R.O. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol. Cell Biol., 2003, 23, 8306.
42. Caporali, S.; Falcinelli, S.; Starace, G.; Russo, M.T.; Bonmassar, E.; Jiricny, J.; D'Atri, S. DNA damage induced by temozolomide signals to both ATM and ATR: Role of the mismatch repair system. Mol. Pharmacol., 2004, 66, 478.
43. Caporali, S.; Levati, L.; Starace, G.; Ragone, G.; Bonmassar, E.; Alvino, E.; D'Atri, S. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol. Pharmacol., 2008, 74, 173.
44. Bocangel, D.B.; Finkelstein, S.; Schold, S.C.; Bhakat, K.K.; Mitra, S.; Kokkinakis, D.M. Multifaceted resistance of gliomas to temozolomide. Clin. Cancer Res., 2002, 8, 2725.
45. Hirose, Y.; Katayama, M.; Mirzoeva, O.K.; Berger, M.S.; Pieper, R.O. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res., 2005, 65, 4861.
46. Dantzer, F.; Shreiber, V.; Niedergang, C.; Trucco, C.; Flatter, E.; De La Rubia, G.; Oliver, J.; rolli, V.; Menissier-de Murcia, J.; De Murcia, G. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie, 1999, 81, 69.
47. Schreiber, V.; Amé, J.C.; Dollé, P.; Schultz, I.; Rinaldi, B.; Fraulob, V.; Ménissier-de Murcia, J.; de Murcia, G. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem., 2002, 277, 23028.
48. Engelward, B.P.; Allan, J.M., Dreslin, A.J.; Kelly, J.D.; Wu, M.M.; Gold, B.; Samson, L.D. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J. Biol. Chem., 1998, 273, 5412.
49. Fronza, G.; Gold, B. The biological effects of N3-methyladenine. J. Cell Biochem., 2004, 91, 250.
50. Kurzen, H.; Schmitt, S.; Naher, H.; Mohler, T. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs, 2003, 14, 515.
51. Tentori, L.; Leonetti, C.; Aquino, A. Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: Role of alpha-6 integrin phosphorylation. Eur. J. Cancer, 1995, 31, 746.
52. Wick, W.; Wick, A.; Schulz, J.B.; Dichgans, J.; Rodemann, H.P.; Weller, M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res., 2002, 62, 1915.
53. Vera, K.; Djafari, L.; Faivre, S.; Guillamo, J.S.; Djazouli, K.; Osorio, M.; Parker, F.; Cioloca, C.; Abdulkarim, B.; Armand, J.P.; Raymond, E. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann. Oncol., 2004, 15, 161.
54. Tubbs, J.L.; Pegg, A.E.; Tainer, J.A. DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair (Amst), 2007, 6, 1100.
55. Daniels, D.S.; Woo, T.T.; Luu, K.X.; Noll, D.M.; Clarke, N.D.; Pegg, A.E.; Tainer, J.A. DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nat. Struct. Mol. Biol., 2004, 11, 714.
56. Margison, G.P.; Povey, A.C.; Kaina, B.; Santibéñez Koref, M.F. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis, 2003, 24, 625.
57. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.; Hau, P.; Mirimanoff, R.O.; Cairncross, J.G.; Janzer, R,C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352, 997
58. Rabik, C.A.; Njoku, M.C.; Dolan, M.E. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat. Rev., 2006, 32, 261.
59. Quinn, J.A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M.E.; Delaney, S.M.; Vredenburgh, J.; Rich, J.; Friedman, A.H.; Reardon, D.A.; Sampson, J.H.; Pegg, A.E.; Moschel, R.C.; Birch, R.; McLendon, R.E.; Provenzale, J.M.; Gururangan, S.; Dancey, J.E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J.E. 2nd.; Bigner, D.D.; Friedman, H.S. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol., 2005, 23, 7178.
60. Broniscer, A.; Gururangan, S.; MacDonald, T.J.; Goldman, S.; Packer, R.J.; Stewart, C.F.; Wallace, D.; Danks, M.K.; Friedman, H.S.; Poussaint, T.Y.; Kun, L.E.; Boyett, J.M.; Gajjar, A. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: A pediatric brain tumor consortium report. Clin. Cancer Res., 2007, 13, 6712.
61. Warren, K.E.; Aikin, A.A.; Libucha, M.; Widemann, B.C.; Fox, E.; Packer, R.J.; Balis, F.M. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J. Clin. Oncol., 2005, 23, 7646.
62. Friedman, H.S.; Pluda, J.; Quinn, J.A.; Ewesuedo, R.B.; Long, L.; Friedman, A.H.; Cokgor, I.; Colvin, O.M.; Haglund, M.M.; Ashley, D.M.; Rich, J.N.; Sampson, J.; Pegg, A.E.; Moschel, R.C.; McLendon, R.E.; Provenzale, J.M.; Stewart, E.S.; Tourt-Uhlig, S.; Garcia-Turner, A.M.; Herndon, J.E. 2nd; Bigner, D.D.; Dolan, M.E. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol., 2000, 18, 3522
63. Adams, D.M.; Zhou, T.; Berg, S.L.; Bernstein, M.; Neville, K.; Blaney, S.M.; Children's Oncology Group. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: A Children's Oncology Group study. Pediatr. Blood Cancer, 2008, 50, 549.
64. Quinn, J.A.; Pluda, J.; Dolan, M.E.; Delaney, S.; Kaplan, R.; Rich, J.N.; Friedman, A.H.; Reardon, D.A.; Sampson, J.H.; Colvin, O.M.; Haglund, M.M.; Pegg, A.E.; Moschel, R.C.; McLendon, R.E.; Provenzale, J.M.; Gururangan, S.; Tourt-Uhlig, S.; Herndon, J.E. 2nd; Bigner, D.D.; Friedman, H.S. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol., 2002, 20, 2277.
65. Weingart, J.; Grossman, S.A.; Carson, K.A.; Fisher, J.D.; Delaney, S.M.; Rosenblum, M.L.; Olivi, A.; Judy, K.; Tatter, S.B.; Dolan, M.E. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: New approaches to brain tumor therapy CNS consortium trial. J. Clin. Oncol., 2007, 25, 399
66. Friedman, H.S.; Keir, S.; Pegg, A.E.; Houghton, P.J.; Colvin, O.M.; Moschel, R.C.; Bigner, D.D.; Dolan, M.E. O6-benzylguanine-mediated enhancement of chemotherapy. Mol. Cancer Ther., 2002, 1, 943.
67. Wagner, L.M.; McLendon, R.E.; Yoon, K.J.; Weiss, B.D.; Billups, C.A.; Danks, M.K. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin. Cancer Res., 2007, 13, 5418.
68. Houghton, P.J.; Stewart, C.F.; Cheshire, P.J.; Richmond, L.B.; Kirstein, M.N.; Poquette, C.A., Tan, M.; Friedman, H.S.; Brent, T.P. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin. Cancer Res., 2000, 6, 4110.
69. Patel, V.J.; Elion, G.B.; Houghton, P.J.; Keir, S.; Pegg, A.E.; Johnson, S.P.; Dolan, M.E.; Bigner, D.D.; Friedman, H.S. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin. Cancer Res., 2000, 6, 4154.
70. Fishel, M.L.; Delaney, S.M.; Friesen, L.D.; Hansen, R.J.; Zuhowski, E.G.; Moschel, R.C.; Egorin, M.J.; Dolan, M.E. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol. Cancer Ther., 2003, 2, 633.
71. Maki, Y.; Murakami, J.; Asaumi, J.; Tsujigiwa, H.; Nagatsuka, H.; Kokeguchi, S.; Fukui, K.; Kawai, N.; Yanagi, Y.; Kuroda, M.; Tanaka, N.; Matsubara, N.; Kishi, K. Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines. Oral Oncol., 2005, 41, 984.
72. Gibson, A.E.; Arris, C.E.; Bentley, J.; Boyle, F.T.; Curtin, N.J.; Davies, T.G.; Endicott, J.A.; Golding, B.T.; Grant, S.; Griffin, R.J.; Jewsbury, P.; Johnson, L.N.; Mesguiche, V.; Newell, D.R.; Noble, M.E.; Tucker, J.A.; Whitfield, H.J. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J. Med. Chem., 2002, 45, 3381.
73. Fishel, M.L.; Newell, D.R.; Griffin, R.J.; Davison, R.; Wang, L.Z.; Curtin, N.J.; Zuhowski, E.G.; Kasza, K.; Egorin, M.J.; Moschel, R.C.; Dolan, M.E. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J. Pharmacol. Exp. Ther., 2005, 312, 206.
74. Middleton, M.R.; Thatcher, N.; McMurry, T.B.; McElhinney, R.S.; Donnelly, D.J.; Margison, G.P. Effect of O6-(4-bromothenyl) guanine on different temozolomide schedules in a human melanoma xenograft model. Int. J. Cancer, 2002, 100, 615.
75. Middleton, M.R.; Margison, G.P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol., 2003, 4, 37.
76. Ranson, M.; Middleton, M.R.; Bridgewater, J.; Lee, S.M.; Dawson, M.; Jowle, D.; Halbert, G.; Waller, S.; McGrath, H.; Gumbrell, L.; McElhinney, R.S.; Donnelly, D.; McMurry, T.B.; Margison, G.P. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res., 2006, 12, 1577
77. Ranson, M.; Hersey, P.; Thompson, D.; Beith, J.; McArthur, G.A.; Haydon, A.; Davis, I.D.; Kefford, R.F.; Mortimer, P.; Harris, P.A.; Baka, S.; Seebaran, A.; Sabharwal, A.; Watson, A.J.; Margison, G.P.; Middleton, M.R. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J. Clin. Oncol., 2007, 25, 2540.
78. Caporaso, P.; Turriziani, M.; Venditti, A.; Marchesi, F.; Buccisano, F.; Tirindelli, M.C.; Alvino, E.; Garbin, A.; Tortorelli, G.; Toppo, L.; Bonmassar, E.; D'Atri, S.; Amadori, S. Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. DNA Repair (Amst), 2007, 6, 1179.
79. Liu, L.; Schwartz, S.; Davis, B.M.; Gerson, S.L. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Cancer Res., 2002, 62, 3070.
80. Jansen, M.; Sorg, U.R.; Ragg, S.; Flasshove, M.; Seeber, S.; Williams, D.A.; Moritz, T. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther., 2002, 9, 737.
81. Woolford, L.B.; Southgate, T.D.; Margison, G.P.; Milsom, M.D.; Fairbairn, L.J. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J. Gene Med., 2006, 8, 29.
82. Tentori, L.; Graziani, G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res., 2005, 52, 25.
83. Zaremba, T.; Curtin, N.J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem., 2007, 7, 515.
84. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434, 917.
85. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature, 2005, 434, 913.
86. Tentori, L.; Lacal, P.M.; Muzi, A.; Dorio, A.S.; Leonetti, C.; Scarsella, M.; Ruffini, F.; Xu, W.; Min, W.; Stoppacciaro, A.; Colarossi, C.; Wang, Z.Q.; Zhang, J.; Graziani, G. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer, 2007, 43, 2124.
87. Tentori, L.; Muzi, A.; Dorio, A.S.; Bultrini, S.; Mazzon, E.; Lacal, P.M.; Shah, G.M.; Zhang, J.; Navarra, P.; Nocentini, G.; Cuzzocrea, S.; Graziani, G. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur. J. Cancer, 2008, 44, 1302.
88. Pellicciari, R.; Camaioni, E.; Costantino, G.; Formentini, L.; Sabbatini, P.; Venturoni, F.; Eren, G.; Bellocchi, D.; Chiarugi, A.; Moroni, F. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. Chem. Med. Chem., 2008, 3, 914.
89. Langelier, M.F.; Servent, K.M.; Rogers, E.E.; Pascal, J.M. A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. J. Biol. Chem., 2008, 283, 4105.
90. Tentori, L.; Portarena, I.; Bonmassar, E.; Graziani, G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ., 2001, 8, 457.
91. Plummer, E.R.; Lorigan, P.; Evans, J; Steven, N.; Middleton, M.; Wilson, R.; Snow, K.; Dewji, R.; Calvert, H. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J. Clin. Oncol., 2006, 24, 8013.
92. Taverna, P.; Liu, L.; Hwang, H.S.; Hanson, A.J.; Kinsella, T.J.; Gerson, S.L. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat. Res., 2001, 485, 269.
93. Fishel, M.L.; He, Y.; Smith, M.L.; Kelley, M.R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin. Cancer Res., 2007, 13, 260
94. Liu, L.; Nakatsuru, Y; Gerson, S.L. Base excision repair as a therapeutic target in colon cancer. Clin. Cancer Res., 2002, 8, 2985.
95. Wilson 3rd, D.M.; Barsky, D. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mut. Res., 2001, 485, 283.
96. Bobola, M.S.; Blank, A.; Berger, M.S.; Stevens, B.A.; Silber JR. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin. Cancer Res., 2001, 7, 3510.
97. Silber, J.R.; Bobola, M.S.; Blank, A.; Schoeler, K.D.; Haroldson, P.D.; Huynh, M.B.; Kolstoe, D.D. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin. Cancer Res., 2002, 8, 3008.
98. Bobola, M.S.; Finn, L.S.; Ellenbogen, R.G.; Geyer, J.R.; Berger, M.S.; Braga, J.M.; Meade, E.H.; Gross, M.E.; Silber, J.R. Apurinic/ apyrimidinic endonuclease activity is associated with response response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin. Cancer Res., 2005, 11, 7405.
99. Trivedi, R.N.; Wang, X.H.; Jelezcova, E.; Goellner, E.M.; Tang, J.; Sobol, R.W. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol. Pharmacol., 2008, 74, 505.
100. Gruber, M.L.; Buster, W.P. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am. J. Clin. Oncol., 2004, 27, 33.
101. Loghin, M.E.; Prados, M.D.; Wen, P.; Junck, L.; Lieberman, F.; Fine, H.; Fink, K.L.; Metha, M.; Kuhn, J.; Lamborn, K.; Chang, S.M.; Cloughesy, T.; DeAngelis, L.M.; Robins, I.H.; Aldape, K.D.; Yung, W.K. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A north american brain tumor consortium study. Clin. Cancer Res., 2007, 13, 7133.
102. Choong, N.W.; Mauer, A.M.; Hoffman, P.C.; Rudin, C.M.; Winegarden, J.D. 3rd.; Villano, J.L.; Kozloff, M.; Wade, J.L. 3rd.; Sciortino, D.F.; Szeto, L.; Vokes, E.E. Phase I trial of erlotinibbased multimodality therapy for inoperable stage III non-small cell lung cancer. J. Thorac. Oncol., 2006, 1, 245.
103. Tentori, L.; Leonetti, C.; Scarsella, M.; Muzi, A.; Mazzon, E.; Vergati, M.; Forini, O.; Lapidus, R.; Xu, W.; Dorio, A.S.; Zhang, J.; Cuzzocrea, S.; Graziani, G. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/ temozolomide efficacy against colon carcinoma. FASEB J., 2006, 20, 1709.
104. Korones, D.N.; Smith, A.; Foreman, N.; Bouffet, E. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr. Blood Cancer, 2006, 47, 37.
105. Terasaki, M.; Bouffet, E.; Katsuki, H.; Fukushima, S.; Shigemori, M. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg. Neurol., 2008, 69, 46.
106. Bafaloukos, D.; Gogas, H.; Georgoulias, V.; Briassoulis, E.; Fountzilas, G.; Samantas, E.; Kalofonos, Ch.; Skarlos, D.; Karabelis, A.; Kosmidis, P. Temozolomide in combination with docetaxel in patients with advanced melanoma: A phase II study of the Hellenic Cooperative Oncology Group. J. Clin. Oncol., 2002, 20, 420.
107. Gounaris, I.; Rahamim, J.; Shivasankar, S.; Earl, S.; Lyons, B.; Yiannakis, D. Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma. Anticancer Drugs, 2007, 18, 1227.
108. Piccioni, D.; D'Atri, S.; Papa, G.; Caravita, T.; Franchi, A.; Bonmassar, E.; Graziani, G. Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J. Chemother., 1995, 7, 224.
109. D'Atri, S.; Graziani, G.; Lacal, P.M.; Nisticò, V.; Gilberti, S.; Faraoni, I.; Watson, A.J.; Bonmassar, E.; Margison, G.P. Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J. Pharmacol. Exp. Ther., 2000, 294, 664.
110. Britten, C.D.; Rowinsky, E.K.; Baker, S.D.; Agarwala, S.S.; Eckardt, J.R.; Barrington, R.; Diab, S.G.; Hammond, L.A.; Johnson, T.; Villalona-Calero, M.; Fraass, U.; Statkevich, P.; Von Hoff, D.D.; Eckhardt, S.G.A. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin. Cancer Res., 1999, 5, 1629.
111. Cortot, A.B.; Gerinière, L.; Robinet, G.; Breton, J.L.; Corre, R.; Falchero, L.; Berard, H.; Gimenez, C.; Chavaillon, J.M.; Perol, M.; Bombaron, P.; Mercier, C.; Souquet, P.J; Groupe Lyon-Saint-Etienne d'Oncologie Thoracique; Groupe Français de Pneumo-Cancérologie. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: A GLOT-GFPC study. Ann. Oncol., 2006, 17, 1412.
112. Tas, F.; Argon, A.; Camlica, H.; Topuz, E. Temozolomide in combination with cisplatin in patients with metastatic melanoma: A phase II trial. Melanoma Res., 2005, 15, 543.
113. Salmaggi, A.; Silvani, A.; Eoli, M.; Lamperti, E.; Boiardi, A. Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: A case report. Neurol. Sci., 2002, 23, 257.
114. Jaeckle, K.A.; Hess, K.R.; Yung, W.K.; Greenberg, H.; Fine, H.; Schiff, D.; Pollack, I.F.; Kuhn, J.; Fink, K.; Mehta, M.; Cloughesy, T.; Nicholas, M.K., Chang, S.; Prados, M. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium study. J. Clin. Oncol., 2003, 21, 2305.
115. Butowski, N.; Prados, M.D.; Lamborn, K.R.; Larson, D.A.; Sneed, P.K.; Wara, W.M.; Malec, M.; Rabbitt, J.; Page, M.; Chang, S.M. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int. J. Radiat. Oncol. Biol. Phys., 2005, 61, 1454
116. Atkins, M.B.; Gollob, J.A.; Sosman, J.A.; McDermott, D.F.; Tutin, L.; Sorokin, P.; Parker, R.A.; Mier, J.W. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin. Cancer Res., 2002, 8, 3075.
117. Ron, I.G.; Sarid, D.; Ryvo, L.; Sapir, E.E.; Schneebaum, S.; Metser, U.; Asna, N.; Inbar, M.J.; Safra, T. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: A phase II study. Melanoma Res., 2006, 16, 65.
118. De Gast, G.C.; Batchelor, D.; Kersten, M.J.; Vyth-Dreese, F.A.; Sein, J.; van de Kasteele, W.F.; Nooijen, W.J.; Nieweg, O.E.; de Waal, M.A.; Boogerd, W. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br. J. Cancer, 2003, 88, 175.
119. Weber, R.W.; O'Day, S.; Rose, M.; Deck, R.; Ames, P.; Good, J.; Meyer, J.; Allen, R.; Trautvetter, S.; Timmerman, M.; Cruickshank, S.; Cook, M.; Gonzalez, R.; Spitler, L.E. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J. Clin. Oncol., 2005, 23, 8992.
120. Chakravarti, A.; Erkkinen, M.G.; Nestler, U.; Stupp, R.; Mehta, M.; Aldape, K.; Gilbert, M.R.; Black, P.M.; Loeffler, J.S. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin. Cancer Res., 2006, 12, 4738.
121. Kil, W.J.; Cerna, D.; Burgan, W.E.; Beam, K.; Carter, D.; Steeg, P.S.; Tofilon, P.J.; Camphausen, K. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin. Cancer Res., 2008, 14, 931.
122. Brandsma, D.; Stalpers, L.; Taal, W.; Sminia, P.; van den Bent, M.J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol., 2008, 9, 453
123. Zhou, Q.; Guo, P.; Wang, X.; Nuthalapati, S.; Gallo. J.M. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J. Pharmacol. Exp. Ther., 2007, 321, 265.
124. Kim, J.T.; Kim, J.S.; Ko, K.W.; Kong, D.S.; Kang, C.M.; Kim, M.H.; Son, M.J.; Song, H.S.; Shin, H.J.; Lee, D.S.; Eoh, W.; Nam, D.H. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol. Rep., 2006, 16, 33.
125. Ku, G.Y.; Krol, G.; Ilson, D.H. Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J. Clin. Oncol., 2007, 25, e14.
126. Lai, A.; Filka, E.; McGibbon, B.; Nghiemphu, P.L.; Graham, C.; Yong, W.H.; Mischel, P.; Liau, L.M.; Bergsneider, M.; Pope, W.; Selch, M.; Cloughesy, T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int. J. Radiat. Oncol. Biol. Phys., 2008, 71, 1372.
127. Ma, J.; Li, S.; Reed, K.; Guo, P.; Gallo, J.M. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J. Pharmacol. Exp. Ther., 2003, 305, 833.
128. Claes, A.; Wesseling, P.; Jeuken, J.; Maass, C.; Heerschap, A.; Leenders, W.P. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol. Cancer Ther., 2008, 7, 71.
129. Kumar, S.; Rajkumar, S.V. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur. J. Cancer, 2006, 42, 1612.
130. Hwu, W.J.; Krown, S.E.; Panageas, K.S.; Menell, J.H.; Chapman, P.B.; Livingston, P.O.; Williams, L.J.; Quinn, C.J.; Houghton, A.N. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J. Clin. Oncol., 2002, 20, 2610.
131. Hwu, W.J.; Krown, S.E.; Menell, J.H.; Panageas, K.S.; Merrell, J.; Lamb, L.A.; Williams, L.J.; Quinn, C.J.; Foster, T.; Chapman, P.B.; Livingston, P.O.; Wolchok, J.D., Houghton, A.N. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol., 2003, 21, 3351.
132. Krown, S.E.; Niedzwiecki, D.; Hwu, W.J.; Hodgson, L.; Houghton, A.N.; Haluska, F.G; Cancer and Leukemia Group B. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: High rate of thromboembolic events (CALGB 500102). Cancer, 2006, 107, 1883.
133. Kulke, M.H.; Stuart, K.; Enzinger, P.C.; Ryan, D.P.; Clark, J.W.; Muzikansky, A.; Vincitore, M.; Michelini, A.; Fuchs, C.S. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol., 2006, 24, 401.
134. Stupp, R.; Goldbrunner, R.; Neyns, B.; Schlegel, U.; Clement, P.; Grabenbauer, G.G.; Hegi, M.E.; Nippgen, J.; Picard, M.; Weller, M. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J. Clin. Oncol., 2007, 25, 2000.
135. Tentori, L.; Dorio, A.S.; Muzi, A.; Lacal, P.M.; Ruffini, F.; Navarra, P.; Graziani, G. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol. Rep., 2008, 19, 1039.
136. Matheson, S.L.; McNamee, J.; Jean-Claude, B.J. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: A novel tumor targeting strategy. J. Pharmacol. Exp. Ther., 2001, 296, 832.
137. Matheson, S.L.; McNamee, J.; Jean-Claude, B.J. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother. Pharmacol., 2003, 51, 20.
138. Prados, M.D.; Lamborn, K.R.; Chang, S.; Burton, E.; Butowski, N.; Malec, M.; Kapadia, A.; Rabbitt, J.; Page, M.S.; Fedoroff, A.; Xie, D.; Kelley, S.K. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol., 2006, 8, 67.
139. Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; Sathornsumetee, S.; Rich, J.N.; Quinn, J.A.; Lagattuta, T.F.; Egorin, M.J.; Gururangan, S.; McLendon, R.; Herndon, Ii.; J.E., Friedman, A.H.; Salvado, A.J.; Friedman, H.S. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. Neuro Oncol., 2008, 10, 330.